The MedWatch December 2012 Safety Labeling Changes posting includes 42 products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.

The "Summary Page" provides a listing of drug names and safety labeling sections revised:

http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm332340.htm

The following drugs had modifications to the BOXED WARNING, CONTRAINDICATIONS and/or WARNINGS sections:

• Altabax (Retapamulin)
• Antara (Fenofibric Acid)
• Celexa (Citalopram Hydrobromide)   
• Chantix (Varenicline)
• Edurant (Rilpivirine)    
• Effexor (Venlafaxine Hydrochloride)
• Effexor XR (Venlafaxine Hydrochloride)
• Fibricor (Fenofibric Acid) 
• Horizant (Gabapentin Enacarbil)    
• Incivek (Telaprevir) 
• Lexapro ( Escitalopram Oxalate)
• Omeprazole Sodium Bicarbonate and Magnesium Hydroxide
• Omontys (Peginesatide)    
• Paxil (Paroxetine Hydrochloride)
• Pexeva (Paroxetine Mesylate)
• Pradaxa (Dabigatran Etexilate)
• Pristiq (Desvenlafaxine)
• Sabril (Vigabatrin)  
• Surmontil (Trimipramine Maleate)   
• Tamiflu (Oseltamivir Phosphate)
• Venlafaxine  
• Viibryd (Vilazodone HCL)
• Xyrem (Sodium Oxybate)
• Zoloft (Sertraline Hydrochloride)      
• Zytiga (Abiraterone Acetate)

Source: FDA